

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,132,530 B2
APPLICATION NO. : 10/633843
DATED : November 7, 2006
INVENTOR(S) : C. Frank Bennett and Kenneth Dobie

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On title page, item (56), References Cited, OTHER PUBLICATIONS, right hand column, Alisky et al. reference, please delete "lateral" and insert therefore --lateral--

On title page, item (74), Attorney, Agent, or Firm, please delete "Knobbe Martens Olson & Bear LLP" and insert therefore --Isis Pharmaceuticals, Inc. Patent Department and Knobbe Martens Olson & Bear LLP--

On title page 2, OTHER PUBLICATIONS, left hand column, Trotti et al. reference, please delete "SODI" and insert therefore --SOD1--

Column 9, line 18, please delete "-CH₂-O-N(CH₃)-CH₂-" and insert therefore --CH₂-O-N(CH₃)-CH₂--

Column 9, line 34, please delete "O(CH₂)_nCH₃" and insert therefore --O(CH₂)_nCH₃--

Column 9, line 61, please delete "(-CH₂)_n" and insert therefore --(-CH₂)_n--

Column 20, line 16, please delete "(S0750)" and insert therefore --(SO750)--

Column 20, line 17, please delete "(DA0750)" and insert therefore --(DAO750)--

Column 29, line 47, please delete "2' -deoxy-21-fluoroadenosine" and insert therefore --2'-deoxy-2'- fluoroadenosine--

Column 31, line 17, please delete "2'-O-Methoxyethyl-51-O-dimethoxytrityl-5-methyluri-" and insert therefore --2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluri- --

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,132,530 B2
APPLICATION NO. : 10/633843
DATED : November 7, 2006
INVENTOR(S) : C. Frank Bennett and Kenneth Dobie

Page 2 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 32, line 23, please delete "(L) Tetrazole" and insert therefore --L).

Tetrazole--

Column 35, line 41, please delete "bamoyl-2¹-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4'-" and insert therefore --bamoyl-2'-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4' --

Column 36, line 65, please delete "31-Deoxy-3'-amino" and insert therefore --3'-Deoxy-3'-amino--

Column 40, line 48, please delete "TCCGTCATCGCTCCTCAGGG" and insert therefore --TCCGTCATCGCTCCTCAGGG--

Column 40, lines 52-53, please delete "ATGCATTCTGCCCCCAAGGA" and insert therefore --ATGCATTCTGCCCCCAAGGA--

Column 41, line 12, please delete "poly(A)+mRNA" and insert therefore --poly(A)+ mRNA--

Column 41, line 56, please delete "Poly(A)+mRNA" and insert therefore --Poly(A)+ mRNA--

Column 41, line 57, please delete "Poly(A)+mRNA" and insert therefore --Poly(A)+ mRNA--

Column 41, line 59, please delete "poly(A)+mRNA" and insert therefore --poly(A)+ mRNA--

Column 43, line 52, please delete "MULV" and insert therefore --MuLV--

Column 87, Claim 9, line 43, please delete "chiracric" and insert therefore --chimeric--

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,132,530 B2
APPLICATION NO. : 10/633843
DATED : November 7, 2006
INVENTOR(S) : C. Frank Bennett and Kenneth Dobie

Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 88, Claim 13, line 24, please delete "NO;3)" and insert therefore
--NO:3)--

Column 88, Claim 13, line 25, after "SEQ ID NO. 15" please insert --, wherein
said antisense compound is an antisense oligonucleotide,--

Column 88, Claim 22, lines 46-47, please delete "22. The composition of claim
20 wherein the compound is an antisense oligonucleotide."

Signed and Sealed this

Eleventh Day of September, 2007

A handwritten signature in black ink, appearing to read "Jon W. Dudas". The signature is stylized with a large, looped initial "J" and a distinct "D".

JON W. DUDAS
Director of the United States Patent and Trademark Office